UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2019

FULGENT GENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

81-2621304

001-37894

Delaware

(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)			
4978 Santa Anita Avenue, Su Temple City, California		91780			
(Address of Principal Executive	Offices)	(Zip Code)			
	(626) 350-0537 (Registrant's telephone number, including	g area code)			
Check the appropriate box below if the Form 8-K provisions:	filing is intended to simultaneously satisfy t	the filing obligation of the registrant under any of the following			
☐ Written communications pursuant to Rule 425	5 under the Securities Act (17 CFR 230.425)			
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)					
☐ Pre-commencement communications pursuan	t to Rule 14d-2(b) under the Exchange Act	(17 CFR 240.14d-2(b))			
☐ Pre-commencement communications pursuan	t to Rule 13e-4(c) under the Exchange Act	(17 CFR 240.13e-4(c))			
Securities registered pursuant to Section 12(b) of t	he Act:				
Title of each class	Trading Symbol(s)	Name of each exchange on which registered			
Common Stock, par value \$0.0001 per sha		The Nasdaq Stock Market (Nasdaq Global Market)			
Indicate by check mark whether the registrant is a or Rule 12b-2 of the Securities Exchange Act of 1		Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)			
Emerging growth company ⊠					

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 30, 2019, Fulgent Genetics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") at its offices in El Monte, California. An aggregate of 18,287,400 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting as of April 5, 2019, the record date for the Annual Meeting. Of these shares, 16,295,709 shares were present in person or by proxy at the Annual Meeting, constituting a quorum of 89%. The Company's stockholders considered and voted on two proposals at the Annual Meeting, and cast their votes on each such proposal as set forth below.

Proposal 1: To elect four directors, each to serve a one-year term until the 2020 annual meeting of the Company's stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal. The results of the voting on Proposal 1 were as follows:

Directors	For	Withheld	Broker Non-Votes
Ming Hsieh	12,740,870	78,500	3,476,339
John Bolger	12,739,870	79,500	3,476,339
James J. Mulay (Mulé), I.Ph.D.	12,740,870	78,500	3,476,339
Yun Yen, M.D., Ph.D., F.A.C.P.	12,731,751	87,619	3,476,339

Proposal 2: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the voting on Proposal 2 were as follows:

For	Against	Abstain	Broker Non-Votes
16,189,660	86,282	19,767	-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 3, 2019 FULGENT GENETICS, INC.

By: /s/ Paul Kim

Name: Paul Kim

Title: Chief Financial Officer